#FANTAVISION FINISH UCRR ONESHOT ACTIVATOR#

We produced seven Ad26 vectors that expressed SARS-CoV-2 S variants that reflected different leader sequences, antigen forms and stabilization mutations: (i) tissue plasminogen activator (tPA) leader sequence with full-length S (tPA.S) 12 (ii) tPA leader sequence with full-length S and mutation of the furin cleavage site and two proline-stabilizing mutations (tPA.S.PP) 13, 14, 15 (iii) wild-type leader sequence with native full-length S (S) (iv) wild-type leader sequence with S and deletion of the cytoplasmic tail (S.dCT) 16 (v) tandem tPA and wild-type leader sequences with full-length S (tPA.WT.S) 12 (vi) wild-type leader sequence with S with deletion of the transmembrane region and cytoplasmic tail reflecting the soluble ectodomain, with mutation of the furin cleavage site, proline-stabilizing mutations, and a foldon trimerization domain (S.dTM.PP) 15 and (vii) wild-type leader sequence with full-length S and mutation of the furin cleavage site and proline-stabilizing mutations (S.PP) (Fig. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed, is currently being evaluated in clinical trials. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge.

Fifty-two rhesus macaques ( Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes 9, 10.

Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Nature volume 586, pages 583–588 ( 2020) Cite this articleĪ safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1, 2, 3, 4, 5, 6, 7, 8. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Fantavision finish ucrr oneshot